Resumen
Background The COPD Assessment Test (CAT) is a valid disease-specific questionnaire measuring health status. However, knowledge concerning its use regarding patient and disease characteristics remains limited. Our main objective was to assess the degree to which the CAT score varies and can discriminate between specific patient population groups. Methods The Canadian Cohort Obstructive Lung Disease (CanCOLD) is a random-sampled, population-based, multicenter, prospective cohort that includes subjects with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] classifications 1 to 3). The CAT questionnaire was administered at three visits (baseline, 1.5 years, and 3 years). The CAT total score was determined for sex, age groups, smoking status, GOLD classification, exacerbations, and comorbidities. Results A total of 716 subjects with COPD were included in the analysis. The majority of subjects (72.5%) were not previously diagnosed with COPD. The mean FEV1/FVC ratio was 61.1 ± 8.1%, with a mean FEV1 % predicted of 82.3 ± 19.3%. The mean CAT scores were 5.8 ± 5.0, 9.6 ± 6.7, and 16.1 ± 10.0 for GOLD 1, 2, and 3+ classifications, respectively. Higher CAT scores were observed in women, current smokers, ever-smokers, and subjects with a previous diagnosis of COPD. The CAT was also able to distinguish between subjects who experience exacerbations vs those who had no exacerbation. Conclusions These results suggest that the CAT, originally designed for use in clinically symptomatic patients with COPD, can also be used in individuals with mild airflow obstruction and newly diagnosed COPD. In addition, the CAT was able to discriminate between sexes and subjects who experience frequent and infrequent exacerbations. Trial Registry ClinicalTrials.gov; No.: NCT00920348; Study ID No.: IRO-93326.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 1069-1079 |
| Número de páginas | 11 |
| Publicación | Chest |
| Volumen | 150 |
| N.º | 5 |
| DOI | |
| Estado | Published - nov. 1 2016 |
Nota bibliográfica
Funding Information:Financial/nonfinancial disclosures: The authors have reported to CHEST the following: W. C. T. reports grants from the Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants, 93326) with industry partners AstraZeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., and Pfizer Canada Ltd. during the conduct of the study. Over the past 3 years, K. R. C. has received compensation for consulting with AstraZeneca, Baxter, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Kamada, Novartis, Nycomed, Roche, and Telacris; has undertaken research funded by Amgen, AstraZeneca, Baxter, Boehringer-Ingelheim, CSL Behring, Forest Labs, GlaxoSmithKline, Grifols, Novartis, Roche, and Takeda; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Grifols, Merck Frosst, Novartis, Pfizer, and Takeda. K. R. C. also holds the GSK-CIHR Research Chair in Respiratory Health Care Delivery at the University Health Network. P. H. reports the following: speakers bureau activities with AstraZeneca, Grifols, and Novartis; and industry advisory committee member for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Merck, and Novartis. D. D. M. has acted as a consultant for AstraZeneca, Boehringer-Ingelheim, the Canadian Foundation for Healthcare Improvement, GlaxoSmithKline, Health Canada, the Lung Association of Saskatchewan, Saskatoon Health Region, and the Saskatchewan Ministry of Health; received research funding (held and managed by the University of Saskatchewan) from AstraZeneca, Boehringer-Ingelheim, Canada Health Infoway, the Canadian Institute of Health Research, GlaxoSmithKline, Novartis, Saskatchewan Health Research Foundation, and Schering-Plough; holds fiduciary positions with the Lung Health Institute of Canada and the University of Saskatchewan Confucius Institute; and is an employee of the University of Saskatchewan. F. M. reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, grants from Nycomed, and grants and personal fees from Novartis (outside the submitted work); all fees are pooled with other revenues of the group of pulmonologists of which F. M. is a member, and then shared among members of the group. F. M. holds a CIHR/GSK research Chair on COPD at Université Laval. D. E. O. serves as a consultant to Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Astra Zeneca; serves on the advisory boards of Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca; has participated in talks for Boehringer Ingelheim, Novartis, and AstraZeneca; has received research grant support from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca, and Novartis; and has received monetary assistance from Novartis to attend international meetings. B. L. W. reports receiving speakers bureau compensation and advisory board work from AstraZeneca and Novartis, as well as travel sponsorship from AstraZeneca. J. B. reports receiving research grants administered by Research Institute of the MUHC for FRQS, CIHR, RI MUHC and the pharma industry consortium with Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. None declared (N. G., L. P., A. B., J. M. F., P. Z. L., S. D. A., D. S.).
Publisher Copyright:
© 2016
ASJC Scopus Subject Areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine